<DOC>
	<DOCNO>NCT00142168</DOCNO>
	<brief_summary>The purpose study determine number patient Waldenstrom 's macroglobulinemia benefit treatment CC-5103 ( lenalidomide ) rituximab , side effect long benefit last .</brief_summary>
	<brief_title>CC-5013 ( Lenalidomide ) Rituximab Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>- The study drug CC-5103 ( lenalidomide ) administer orally daily 21 day follow 7 day CC-5103 ( lenalidomide ) ( one 28 day treatment cycle ) . This cycle repeat every 28 day long patient tolerate medication disease progression . - Starting second week , patient begin treatment rituximab intravenously week 4 week ( week 2-5 ) . Prior treatment , patient receive medication prevent reduce side effect rituximab ( benadryl , tylenol possible decadron ) . During infusion , patient ' blood pressure pulse monitor frequently rate infusion may decrease depend upon side effect . Blood work also perform week . - On week 12 disease status evaluate . A physical exam , blood test , CT scan bone marrow biopsy may repeat necessary fully evaluate disease . If disease go away completely , test may repeat confirm . - If disease get bad 12 week , patient remove study . - If disease stable get well , patient continue therapy . During week 13-16 rituximab infusion repeat CC-5103 continue take daily 21 day follow 7 day rest . This 28 day cycle may repeat patient complete 48 week ( 12 month ) treatment long side effect acceptable disease progress . - All patient undergo off-study evaluation include physical exam , blood work , CT scan bone marrow biopsy . If patient complete 78 week therapy disease get bad , evaluate every 12 week determine status disease 2 year .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Clinicopathological diagnosis Waldenstrom 's macroglobulinemia use consensus panel criterion Age 18 year old CD20 positive base previous bone marrow immunohistochemistry flow cytometric analysis All previous cancer therapy , include radiation , hormonal therapy surgery , must discontinue least 4 week prior treatment study Measurable disease , define presence immunoglobulin M paraprotein minimum IgM level equal great 2 time upper limit normal . ECOG performance status 02 Absolute neutrophil count ≥ 100,000,000/L Platelet count ≥ 50,000,000,000/L Hemoglobin &gt; 8 g/dL Serum creatinine &lt; 2.5 mg/dL Total bilirubin &lt; 1.5 mg/dL AST ALT &lt; 2.5 x ULN Disease free prior malignancy fir 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma situ cervix breast Any serious medical condition , laboratory abnormality , psychiatric illness Pregnant lactating woman Prior therapy rituximab CC5103 Known hypersensitivity thalidomide Development erythema nodosum characterize desquamate rash take thalidomide similar drug . Concurrent use anticancer agent treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>CC-5103 ( lenalidomide )</keyword>
	<keyword>rituximab</keyword>
	<keyword>Waldenstrom 's macroglobulinemia</keyword>
</DOC>